Laurel Wealth Advisors (California)’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-15,900	Closed	-$17K	–	443
2019 Q1	$17K	Buy	+15,900	New	+$12.9K	﹤0.01%	404

Laurel Wealth Advisors (California)'s OMED Position: Q2 2019 in Review

Laurel Wealth Advisors (California) sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 15,900 shares — an estimated $17K sold.

Laurel Wealth Advisors (California) first reported a position in OMED in Q1 2019 and held it in 1 quarter. The position peaked at $17K in Q1 2019. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.

Laurel Wealth Advisors (California) reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Laurel Wealth Advisors (California) sold 15,900 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $17K.
Laurel Wealth Advisors (California) first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
Laurel Wealth Advisors (California)'s OncoMed Pharmaceuticals, Inc. position peaked at $17K in Q1 2019.
0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q2 2019, filed 13 Aug 2019.